Genseq are delighted to launch 11 new IS015189:2022 accredited hereditary cancer panels. Genseq offer a range of Hereditary Cancer gene panels (see our website for full details: genseqgroup.com). These are in silico panels based on whole exome sequencing (WES) data. All panels include single nucleotide variants (SNV), small insertions/deletions (indels), and copy number variation (CNV) analysis.
Cancer is a leading cause of death worldwide and it has been estimated that 5-10% of all cancers are hereditary i.e. passed down from one generation to the next. Genetic Testing for the presence of germline genetic variants provides many benefits to patients and their family members and forms an important part of cancer care.
